Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus

Ingrid A. Beck; Rachel Payant; Nicole Ngo-Giang-Huong; Woottichai Khamduang; Laddawan Laomanit; Gonzague Jourdain; Lisa M. Frenkel

doi:10.1016/j.jviromet.2016.03.014

Retour

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus

Article de revue

Avec comité de lecture

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus

Ingrid A. Beck, Rachel Payant, Nicole Ngo-Giang-Huong, Woottichai Khamduang, Laddawan Laomanit, Gonzague Jourdain et Lisa M. Frenkel

Journal of virological methods, Vol.233, pp.51-55

01/07/2016

DOI: https://doi.org/10.1016/j.jviromet.2016.03.014

PMID: 27025356

Résumé

Biochemical Research Methods

Biochemistry & Molecular Biology

Biotechnology & Applied Microbiology

Life Sciences & Biomedicine

Science & Technology

Virology

Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligonucleotide ligation assay (OLA) for HBV lamivudine-resistance was developed and compared to consensus sequencing. Both assays detected drug resistance mutations in 35/64 (54.7%) specimens evaluated, and OLA detected minority mutants in an additional six (9.4%). OLA may offer a sensitive and inexpensive alternative to consensus sequencing for detection of HBV drug resistance in resource-limited settings. (C) 2016 Elsevier B.V. All rights reserved.

Indicateurs

1 Consultations de la notice

Détails

Titre: Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus
Créateurs - sans rôle: Ingrid A. Beck - Seattle Childrens Res Inst, 1900 Ninth Ave,Mailstop JMB 8, Seattle, WA 98101 USA
Rachel Payant - Seattle Childrens Res Inst, 1900 Ninth Ave,Mailstop JMB 8, Seattle, WA 98101 USA
Nicole Ngo-Giang-Huong - Inst Rech Dev, Programs HIV Prevent & Treatment PHPT, Unite Mixte Int 174, Chiang Mai, Thailand
Woottichai Khamduang - Inst Rech Dev, Programs HIV Prevent & Treatment PHPT, Unite Mixte Int 174, Chiang Mai, Thailand
Laddawan Laomanit - Inst Rech Dev, Programs HIV Prevent & Treatment PHPT, Unite Mixte Int 174, Chiang Mai, Thailand
Gonzague Jourdain - Inst Rech Dev, Programs HIV Prevent & Treatment PHPT, Unite Mixte Int 174, Chiang Mai, Thailand
Lisa M. Frenkel - Seattle Childrens Res Inst, 1900 Ninth Ave,Mailstop JMB 8, Seattle, WA 98101 USA
Détails de publication: Journal of virological methods, Vol.233, pp.51-55
Éditeur: Elsevier
Nombre de pages: 5
Note de subvention: ANRS 12179 / Agence Nationale de Recherches sur le Sida et les hepatites virales; ANRS; Agence Nationale de la Recherche (ANR) P30 AI027757 / Center for AIDS Research R01HD 39615 / National Institute of Child Health and Human Development; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) GFATM PRDDC-H-N-008/SSF / Global Fund to fight AIDS, TB and Malaria UM1 AI106716 / International Maternal, Pediatric and Adolescent AIDS Clinical Trials Group
Identifiants: 99147788209311
Unité académique: Maladies Infectieuses et Vecteurs : Ecologie, Génétique, Evolution et Contrôle - MIVEGEC
Langue: English
Type de ressource: Journal article